Biotech

141 companies in this sector.

#	Company	Description	Location	Status	Funding
01	Isomorphic Labs	London-based AI-first drug design and development company spun out of Google DeepMind in 2021. Builds the IsoDDE drug design engine leveraging AlphaFold-derived architectures to design therapeutic candidates across disease areas. CEO Demis Hassabis is also CEO of Google DeepMind.	London, United Kingdom	Private	$2.7B
02	Xaira Therapeutics	South San Francisco-based AI-native biotech co-founded by David Baker (Nobel Chemistry 2024). Uses RFdiffusion generative protein design to discover and develop novel therapeutics. Founded 2023.	South San Francisco, United States	Private	$1.6B
03	Freenome	Biotech company developing AI-powered multiomics blood tests for early cancer detection. Its platform analyzes cell-free DNA, methylation patterns, and protein biomarkers from routine blood draws to screen for cancers in their earliest stages. Lead product SimpleScreen targets FDA approval for colorectal cancer screening.	South San Francisco, California, United States	Private	$1.3B
04	SHINE Technologies	Nuclear fusion company commercializing fusion-based technologies through a phased strategy: industrial testing (FLARE neutron source), medical isotopes (Lu-177 for cancer therapy, Mo-99 for diagnostics), nuclear waste recycling, and ultimately fusion energy. The Cassiopeia facility in Janesville, WI is the largest n.c.a. Lu-177 production facility in North America (200,000 doses/year capacity). Achieved first-ever visible Cherenkov radiation produced by fusion in 2023.	Janesville, US	Private	$1.0B
05	Candid Therapeutics	Candid Therapeutics is a clinical-stage biotechnology company developing novel T-cell engager antibodies to treat autoimmune and inflammatory diseases. The company's platform redirects T-cells to selectively eliminate autoreactive B-cells, with clinical programs spanning five autoimmune indications. Founded by Ken Song after his $4.1B sale of RayzeBio to Bristol Myers Squibb.	San Diego, California, United States	Private	$875M
06	Ginkgo Bioworks	Synthetic biology company that builds an automated platform for programming cells, enabling customers across pharmaceuticals, agriculture, and industrial chemicals to harness the power of biology.	Boston, US	Public	$720M
07	Apeel Sciences	Apeel Sciences develops plant-derived, edible coatings that extend the shelf life of fresh produce by slowing water loss and oxidation. Founded with a Bill and Melinda Gates Foundation grant, the company's FDA-approved coatings are made from lipids found in fruit peels, enabling longer freshness without refrigeration. Used by major retailers including Costco, Kroger, and Walmart.	Goleta, United States	Private	$715M
08	Babylon Health	Babylon Health was a digital healthcare company that used AI to provide virtual consultations, triage, and health monitoring through its mobile app. After partnering with the UK's NHS and expanding globally, the company went public via SPAC at a $4.2 billion valuation in 2021 before collapsing into Chapter 7 bankruptcy in August 2023.	London, United Kingdom	Private	$642M
09	NewLimit	South San Francisco-based longevity biotech using epigenetic reprogramming (Yamanaka-style) to restore youthful cell function. Lead program targets aged human liver cells; first clinical trial planned for 2027. Co-founded 2021 by Coinbase CEO Brian Armstrong, ex-GV's Blake Byers, and computational biologist Jacob Kimmel.	South San Francisco, USA	Private	$605M
10	Cellares	South San Francisco-based first 'Integrated Development and Manufacturing Organization' (IDMO) for cell therapy. Delivered first GMP cell therapy doses to patients in April 2026. 10-year supply deal with Cabaletta Bio. Global Smart Factory network launching 2027. Founded April 2019.	South San Francisco, USA	Private	$532M
11	Science Corp	Neurotechnology company developing a brain-computer interface called Science Eye to restore vision for people with retinal diseases. Uses a thin-film microLED display implanted behind the retina. Founded by Neuralink co-founder Max Hodak.	Alameda, United States	Private	$490M
12	Benchling	Benchling is a cloud-based life sciences R&D platform that helps biotech and pharmaceutical companies manage experiments, track data, and accelerate research and development. The platform replaces physical lab notebooks and spreadsheets with collaborative, AI-ready digital tools used by over 1,200 customers worldwide.	San Francisco, US	Private	$412M
13	Ember Bio AI	Cambridge-based biotech engineering AI-designed antibodies for autoimmune indications.	Cambridge, United States	Private	$369M
14	Coral Bio AI	Cambridge-based biotech engineering AI-designed vaccines for infectious disease prevention.	Cambridge, United States	Private	$364M
15	Ursa Bio	Boston-based biotech engineering AI-designed gene therapies for rare mitochondrial diseases.	Boston, United States	Private	$352M
16	Cedar	Cedar is a healthcare financial technology platform that simplifies patient billing and payment experiences for hospitals, health systems, and medical groups. The platform uses data science and AI to personalize billing communications and optimize payment outcomes, serving over 50 million patients.	New York, United States	Private	$351M
17	CellCentric	Cambridge, UK clinical-stage biotech developing inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed/refractory multiple myeloma and other cancers. Based on the science of Azim Surani at the Gurdon Institute, Cambridge.	Cambridge, United Kingdom	Private	$340M
18	Headway	Headway is a mental health platform building the first national network of therapists who accept insurance. The company handles credentialing, billing, and administrative tasks for therapists, making it easier for patients to find affordable in-network mental health care across all 50 states.	New York, United States	Private	$327M
19	Meadow Bio	Cambridge-based biotech engineering AI-designed cell therapies for rare pediatric autoimmune indications.	Cambridge, United States	Private	$292M
20	Inceptive	Palo Alto-based AI-native biotech designing RNA molecules for therapeutic and vaccine applications using a foundation model trained on biological function data. Co-founded by AlphaFold and AlphaCode contributor Jakob Uszkoreit. Founded 2021.	Palo Alto, United States	Private	$275M
21	Oricell Therapeutics	Chinese clinical-stage biotech developing next-generation CAR-T cell therapies for solid tumors. Lead asset Ori-C101 targets hepatocellular carcinoma (liver cancer), aiming to become the first globally-approved CAR-T for the disease. Pipeline focused on overcoming the historical limitations of CAR-T in solid tumors.	Shanghai, China	Private	$270M
22	Iterative Health	Cambridge, Massachusetts AI-driven healthcare technology and clinical research network (originally Iterative Scopes). Started with computer vision for GI endoscopy and the SKOUT polyp detection system, now expanding into cardiology and obesity clinical trials.	Cambridge, United States	Private	$267M
23	Accolade	Accolade is a personalized health and benefits solutions company that uses technology, data analytics, and clinical expertise to help employers improve healthcare outcomes while controlling costs. The platform connects employees and families to the right care through AI-powered navigation, virtual primary care (PlushCare), and expert medical opinions (2nd.MD).	Plymouth Meeting, United States	Acquired	$235M
24	Ray Therapeutics	Clinical-stage biotechnology company developing optogenetic gene therapies to restore vision in patients with blinding retinal diseases. Delivers bioengineered, highly light-sensitive proteins to targeted retinal cells via a single intravitreal injection. Lead program RTx-015 targets retinitis pigmentosa with FDA RMAT designation. Approach is mutation-agnostic, working across many genetic causes of blindness.	Berkeley, United States	Private	$231M
25	Doctor on Demand	Doctor on Demand was a telehealth platform providing on-demand video visits with board-certified physicians, psychiatrists, and psychologists. In 2021, it merged with Grand Rounds Health to form Included Health, a comprehensive virtual care and navigation platform serving employers and health plans.	San Francisco, United States	Acquired	$223M
26	Masimo	Global medical technology company that develops noninvasive patient monitoring technologies, including Signal Extraction Technology (SET) pulse oximetry. Innovations address limitations in traditional pulse oximetry by providing accurate readings through patient motion and low perfusion. Products used in hospitals worldwide.	Irvine, US	Private	$203M
27	Basecamp Research	London-based bio-foundation-model company that has assembled the largest sequenced biodiversity dataset (BaseData, ~10x larger than the next public dataset) via partnerships with 25 sovereign biodiversity agencies. Foundation model trained for enzyme discovery. Founded 2019.	London, United Kingdom	Private	$190M
28	Orchestra BioMed	Orchestra BioMed is a biomedical innovation company that accelerates high-impact medical technologies through risk-reward sharing partnerships with leading medical device companies. Its lead programs are BackBeat Cardiac Neuromodulation Therapy for hypertension treatment in pacemaker patients and Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease. The company has strategic partnerships with Medtronic and Terumo Corporation.	New Hope, United States	Public	$185M
29	Pearl Bio	SF-based biotech engineering AI-designed protein binders for cardiovascular indications.	San Francisco, United States	Private	$159M
30	Cypress Bio	Boston-based biotech engineering AI-designed base-editing therapies for hereditary blindness.	Boston, United States	Private	$154M
31	Bay Bio	SF-based biotech engineering AI-designed neuro-restorative therapies for Parkinson disease.	San Francisco, United States	Private	$154M
32	Dahlia Bio	Cambridge-based biotech engineering AI-designed antibody-drug conjugates for pediatric leukemia.	Cambridge, United States	Private	$154M
33	GT Medical Technologies	Tempe, Arizona-based medical device maker. Flagship GammaTile is an FDA-cleared bioresorbable radiation implant placed during brain tumor surgery. ROADS RCT data at ASCO 2026: 12-month tumor surgical bed recurrence 1.3% vs 15.4% standard of care; 24-month OS 61.7% vs 35.7%. Founded 2017 by Barrow Neurological Institute team.	Tempe, USA	Private	$153M
34	Anchor Bio	Cambridge-based biotech engineering AI-designed CAR-NK cell therapies for solid tumors.	Cambridge, United States	Private	$149M
35	Coultreon Biopharma	Belgian immunology biotech (formerly Onco3R Therapeutics) developing COL-5671, an oral SIK3 inhibitor targeting psoriasis and ulcerative colitis. The aim is biologic-class efficacy delivered as a once-daily pill, with the lead asset transferred from Galapagos in 2025.	Leuven, Belgium	Private	$148M
36	Wren Biotech	Cambridge-based biotech engineering AI-designed radioligand therapies for oncology indications.	Cambridge, United States	Private	$148M
37	Verdant Bio	Cambridge-based biotech engineering AI-designed protein therapies for chronic kidney disease.	Cambridge, United States	Private	$147M
38	Larch Bio	Cambridge-based biotech engineering AI-designed cell therapies for solid tumor indications.	Cambridge, United States	Private	$146M
39	Magnolia Bio	Cambridge-based biotech engineering AI-designed macrocyclic peptide therapies for cardiovascular disease.	Cambridge, United States	Private	$143M
40	Bloom Bio	Cambridge-based biotech engineering AI-designed monoclonal antibodies for inflammatory bowel disease.	Cambridge, United States	Private	$142M
41	Cove Bio	Cambridge-based biotech building AI-designed protein degrader therapies for oncology.	Cambridge, United States	Private	$139M
42	Dawn Bio	Cambridge-based biotech engineering AI-designed inhaled therapies for asthma and COPD.	Cambridge, United States	Private	$138M
43	Pinnacle Medicines	Pioneer of oral peptide therapeutics that integrates physics-based molecular simulations, AI-enabled design, and advanced peptide chemistry. Pipeline targeting immunology and cardiometabolic diseases.	Doylestown, United States	Private	$134M
44	Sable Bio	SF-based biotech building AI-designed protein degradation therapeutics for oncology.	San Francisco, United States	Private	$134M
45	Tidal Vision	Bellingham, Washington-based sustainable materials company producing chitosan (a biopolymer from waste shrimp shells) for water treatment, textiles, and agriculture applications. Displacing PFAS and formaldehyde-based chemistries. Founded 2015.	Bellingham, United States	Private	$133M
46	Beacon Biosignals	Combines FDA-cleared wearable EEG technology with advanced AI to capture and analyze real-world neural data, enabling breakthroughs across neurology, psychiatry, and sleep medicine. Building the world's largest neurodiagnostic dataset. Making brain function measurable and actionable at scale.	Boston, United States	Private	$132M
47	Pardes Biosciences	Clinical-stage biopharmaceutical company that developed novel oral antiviral therapeutics targeting COVID-19. Went public via SPAC merger in 2021 before being acquired by MediPacific (a Foresite Capital affiliate) in 2023 after its lead candidate failed Phase 2 trials.	Carlsbad, US	Acquired	$127M
48	Cartography Biosciences	Cartography Biosciences is a precision oncology company developing cancer immunotherapies guided by the first comprehensive antigen atlas for immuno-oncology targets. The company's proprietary ATLAS and SUMMIT platforms combine single-cell genomics, proteomics, and computational biology to identify tumor-selective antigens, enabling antibody-based therapies that target tumors more precisely than existing therapeutics.	South San Francisco, United States	Private	$124M
49	CREATE Medicines	Cambridge, MA clinical-stage biotech (formerly Myeloid Therapeutics) developing in vivo CAR therapies that reprogram immune cells (T cells, NK cells, myeloid cells) inside the body using an mRNA plus lipid nanoparticle delivery platform. Lead program CRT-402 targets CD19 for autoimmune disease.	Cambridge, United States	Private	$122M
50	Nurx	Telehealth platform providing accessible and affordable healthcare with prescriptions delivered to patients' doors. Started with birth control and PrEP (HIV prevention), then expanded to STI testing, HPV screening, herpes treatment, migraine care, and dermatology. At its peak, Nurx served over 750,000 active patients. Founded by two Norwegian high school classmates who saw how difficult it was to access basic reproductive healthcare.	-	Acquired	$116M
51	Contraline	Charlottesville-based clinical-stage biopharma developing NES/T Gel (segesterone acetate + testosterone), a reversible male contraceptive gel. Phase 2b complete with 462 couples; Phase 3 expected 2027. Also developing the ADAM hydrogel vas deferens implant. Founded 2015.	Charlottesville, USA	Private	$110M
52	uBiome	uBiome was a biotechnology company that developed technology to sequence and analyze the human microbiome using proprietary machine-learning algorithms. The company offered consumer testing kits and clinical diagnostics (SmartGut, SmartJane) reimbursed by health insurance. uBiome collapsed in 2019 after an FBI raid over healthcare fraud, with its co-founders later indicted for defrauding investors and insurers.	San Francisco, United States	Private	$110M
53	Sunrise Robotics	Boston-based robotics startup building AI-native lab automation for pharmaceutical R&D.	Boston, United States	Private	$109M
54	Crossbow Therapeutics	Biotech developing TCR-mimetic antibody therapies (T-Bolt immunotherapies) to treat cancer. Lead candidate CBX-250 targets myeloid cancers with a Phase 1 trial underway and data expected by end of 2026.	Cambridge, United States	Private	$107M
55	Cradle Bio	Zurich and Amsterdam-based protein engineering platform that lets biologists design and optimize proteins via a generative AI copilot integrated with wet-lab automation. Customers include Johnson & Johnson, Novozymes, and Twist Bioscience. Founded 2021.	Zurich, Switzerland	Private	$103M
56	Stipple Bio	Precision oncology biotech harnessing epitope-level precision to create targeted cancer therapies. The Pointillist Platform identifies tumor-specific cell surface epitopes, enabling antibody-drug conjugates (ADCs) that avoid on-target/off-tumor toxicity. Lead candidate STP-100 expected in clinical studies early 2027.	Cambridge, United States	Private	$100M
57	Tomorrow Health	Tomorrow Health is a technology-driven home healthcare platform that connects patients, health plans, providers, and suppliers to streamline the ordering, delivery, and management of home-based medical equipment and care. The company works with over 125 health plans and health systems.	New York, United States	Private	$93M
58	Immutrin	UK biotech developing next-generation antibody therapy to reverse ATTR amyloidosis (amyloid cardiomyopathy). Co-founded by Nobel Laureate Sir Gregory Winter. Novel antibody selectively binds amyloid fibrils to stimulate targeted immune-mediated clearance.	Cambridge, United Kingdom	Private	$87M
59	Ona Therapeutics	Barcelona-based clinical-stage biotech developing antibody-drug conjugates (ADCs) for treatment-resistant cancers. Lead programs ONA-255 (breast cancer) and ONA-389 (colorectal). Founded 2020.	Barcelona, Spain	Private	$87M
60	R1 Therapeutics	Clinical-stage biopharma developing a first-in-class treatment (AP306) for hyperphosphatemia in chronic kidney disease patients. AP306 is a pan-phosphate transporter inhibitor with a Phase 2b study planned for 2026.	San Francisco, United States	Private	$78M
61	Kanvas Biosciences	Princeton-based spatial biology company building a microbiome drug discovery, screening, and manufacturing platform. Lead candidate KAN-001 is a live biotherapeutic for solid-tumor patients who do not respond to immune checkpoint inhibitors. Spinout from Cornell, founded 2020.	Princeton, United States	Private	$71M
62	Notable Labs	Clinical-stage precision oncology company that built a proprietary Predictive Precision Medicines Platform (PPMP) to bio-simulate cancer treatments and predict patient response. Originally tested combinations of FDA-approved drugs on patient cancer cell samples for blood cancers. Demonstrated 84% accuracy in predicting treatment responses with Stanford.	Foster City, United States	Private	$66M
63	Unnatural Products	Developing orally-delivered macrocyclic peptide therapeutics to address previously undruggable targets. Platform combines parallel experimentation and machine learning, with a Novartis licensing deal worth up to $1.7B in milestones.	Santa Cruz, United States	Private	$62M
64	Kelvin Bio	Boston-based biotech building AI-designed small molecule therapies for CNS neurodegenerative diseases. Runs two IND-enabling programs.	Boston, United States	Private	$57M
65	Ember Bio Sciences	Cambridge-based biotech engineering AI-designed peptide therapeutics for oncology indications.	Cambridge, United States	Private	$57M
66	Sable Bio Sciences	Cambridge-based biotech engineering AI-designed small molecule inhibitors for rare pediatric cancers.	Cambridge, United States	Private	$57M
67	Robin Bio	Cambridge-based biotech engineering AI-designed protein degrader therapies for hematology.	Cambridge, United States	Private	$57M
68	Silver Bio	Cambridge-based biotech engineering AI-designed enzyme therapies for lysosomal storage diseases.	Cambridge, United States	Private	$57M
69	Inlet Bio	Boston-based biotech engineering AI-designed protein binders for pulmonary hypertension.	Boston, United States	Private	$57M
70	Basalt Bio	Cambridge-based biotech engineering AI-designed neuromuscular therapies for rare pediatric diseases.	Cambridge, United States	Private	$57M
71	Fern Bio	Boston-based biotech engineering AI-designed radiopharmaceuticals for solid tumor indications.	Boston, United States	Private	$56M
72	Rhythm Biotech	Boston-based biotech engineering AI-designed heart failure therapeutics for cardiovascular patients.	Boston, United States	Private	$56M
73	Cinder Bio Sciences	Cambridge-based biotech engineering AI-designed RNA therapies for hepatology indications.	Cambridge, United States	Private	$56M
74	Summit Bio	Cambridge-based biotech engineering AI-designed protein therapies for kidney disease.	Cambridge, United States	Private	$56M
75	Aspen Bio	SF-based biotech engineering AI-designed inhaled therapies for pulmonary hypertension.	San Francisco, United States	Private	$56M
76	Dune Bio	Cambridge-based biotech engineering AI-designed antibody-drug conjugates for solid tumor indications.	Cambridge, United States	Private	$56M
77	Vine Bio	Cambridge-based biotech engineering AI-designed protein degrader therapies for autoimmune disease.	Cambridge, United States	Private	$56M
78	Beam Bio	Cambridge-based biotech engineering AI-designed regenerative therapies for chronic wounds.	Cambridge, United States	Private	$56M
79	Tara Bio	Boston-based biotech engineering AI-designed enzyme replacement therapies for rare metabolic disorders.	Boston, United States	Private	$56M
80	NVision	Ulm-based German quantum-tech company hyperpolarizing metabolic molecules to amplify MRI signals roughly 10,000x for real-time disease metabolism imaging. Expanding into quantum computing for drug design. Backed by Abbott as Series B anchor.	Ulm, Germany	Private	$55M
81	Prism Biotech	SF-based biotech building AI-designed protein-language-model targeted therapies for cardiovascular disease.	San Francisco, United States	Private	$55M
82	Fathom Therapeutics	AI and quantum chemistry-driven drug discovery company (formerly Atommap). The Microcosmos engine simulates protein dynamics at atomic resolution roughly 10,000x faster than conventional methods, designing small-molecule medicines for historically undruggable targets.	New York, United States	Private	$54M
83	Petal Bio Sciences	Boston-based biotech engineering AI-designed antibody-drug conjugates for hematologic malignancies.	Boston, United States	Private	$54M
84	Olive Bio	Cambridge-based biotech engineering AI-designed lipid-nanoparticle mRNA therapies for rare pediatric diseases.	Cambridge, United States	Private	$54M
85	Grove Bio Sciences	Boston-based biotech engineering AI-designed cell therapies for autoimmune indications.	Boston, United States	Private	$53M
86	Beacon Bio	Cambridge-based biotech building AI-designed inhaled therapies for chronic respiratory diseases.	Cambridge, United States	Private	$53M
87	Boulevard Biotech	Cambridge-based biotech engineering AI-designed enzyme therapies for metabolic disorders.	Cambridge, United States	Private	$53M
88	ClearNote Health	San Diego-based blood-based early cancer detection company (formerly Camera Health). Avantect pancreatic test plus Virtuoso platform for pancreatic and ovarian cancers. Founded 2018. Operating CEO Dave Mullarkey leads commercial expansion; Kevin Keegan newly named President and COO.	San Diego, USA	Private	$52M
89	Sunday Bio	Boston-based biotech building AI-designed mRNA therapeutics for rare pediatric metabolic disorders.	Boston, United States	Private	$52M
90	Basil Bio	Cambridge-based biotech engineering AI-designed vaccines for infectious disease indications.	Cambridge, United States	Private	$52M
91	Willow Bio	SF-based biotech building AI-designed protein-degradation therapeutics for cancer indications.	San Francisco, United States	Private	$51M
92	Petal Bio	SF-based biotech engineering AI-designed enzyme therapeutics for lysosomal storage disorders.	San Francisco, United States	Private	$51M
93	Prolium Bioscience	Clinical-stage biotech developing PRO-203, a potential best-in-class CD20xCD3 T-cell engager for severe autoimmune diseases including systemic sclerosis and lupus.	New York, New York, United States	Private	$50M
94	Inherent Labs	London-based AI-native science lab building Faraday, a system pairing human researchers with self-improving AI agents to identify which scientific questions are worth pursuing. Emerged from stealth May 2026. Founders are ex-DeepMind researchers; Matt Clifford (Entrepreneurs First) is an advisor.	London, United Kingdom	Private	$50M
95	Coral Bio Sciences	SF-based biotech engineering AI-designed CRISPR base editors for ophthalmic indications.	San Francisco, United States	Private	$50M
96	Aster Bio	SF-based biotech building AI-designed small molecule inhibitors for autoimmune diseases.	San Francisco, United States	Private	$50M
97	Boulevard Bio	Cambridge-based biotech building AI-designed viral vector delivery systems for gene therapy.	Cambridge, United States	Private	$49M
98	Grove Bio	SF-based biotech engineering AI-designed vaccines for infectious disease indications in low-income countries.	San Francisco, United States	Private	$49M
99	Almond Bio	Cambridge-based biotech engineering AI-designed lipid nanoparticle delivery for gene therapies.	Cambridge, United States	Private	$48M
100	Apoha	London and San Francisco-based deep tech company developing 'Liquid State Intelligence': AI models for molecular and material behavior (proteins, food, paints, semiconductors) using novel waveform liquid data. Emerged from stealth at SXSW London 2026. Founded 2022.	London, United Kingdom	Private	$46M
101	Triomics	New York-based oncology-specific AI for cancer centers. Powers clinical trial matching and chart abstraction at MSK, MD Anderson, Yale/Smilow, and Mount Sinai Tisch. Founded 2021 with operations in India.	New York, USA	Private	$37M
102	Human API	Human API is a consumer-controlled health data platform that connects to electronic health record networks, patient portals, pharmacies, labs, wearable devices, and fitness apps through a single secure API. The platform converts health data into actionable intelligence, primarily serving life insurance underwriting, clinical research, and digital health companies.	San Mateo, United States	Acquired	$37M
103	Techcyte	Orem, Utah AI-powered digital pathology platform (Fusion) serving human medical, veterinary, and environmental laboratories. Integrates AI with digitized lab workflows for diagnostic accuracy across cytology, hematology, and parasitology.	Orem, United States	Private	$36M
104	Petal Robotics AI	Boston-based robotics startup building AI-native lab automation for CRO clinical trial workflows.	Boston, United States	Private	$36M
105	Waypoint Bio	New York-based AI-native biotech using spatial pooled screening and computer vision to design in vivo CAR T therapies for solid tumors. Lead program WAY-103. Founded 2021. CTO Patrick Kaifosh previously at CTRL-Labs and Meta Reality Labs.	New York, USA	Private	$35M
106	Coral Health	NYC-based digital health startup building AI-native rare disease diagnosis for pediatric patients.	New York, United States	Private	$34M
107	Waiv	AI precision testing company spun out from Owkin, applying deep neural network analysis to digitized biopsy slides for oncology biomarker discovery, detection, and treatment-response prediction	Paris, France	Private	$33M
108	Kelp Climate	Boulder-based climate-tech startup building AI-native ocean carbon sequestration monitoring for marine carbon credits.	Boulder, United States	Private	$33M
109	Advanced NanoTherapies	Santa Clara-based clinical-stage medtech company developing SirPlux Duo, the first nanoparticle-coated dual-drug (paclitaxel + sirolimus) balloon platform for coronary and peripheral artery disease.	Santa Clara, USA	Private	$31M
110	Coral Climate	Boulder-based climate-tech startup building AI-optimized ocean carbon removal via kelp farming.	Boulder, United States	Private	$31M
111	Secretome Therapeutics	Plano, Texas-based neonatal cardiac progenitor-cell (nCPC) therapy company (formerly NeoProgen). Lead asset STM-01 targets Duchenne muscular dystrophy-associated cardiomyopathy. Founded 2018.	Plano, USA	Private	$30M
112	P2 Science	Connecticut-based green chemistry company converting plant oils and sustainable feedstocks into ingredients for beauty, aroma, polymers, coatings, and crop care. Founded 2009 by Yale Center for Green Chemistry scientists. CEO Oihana Elizalde leads commercial scale-up.	Woodbridge, USA	Private	$23M
113	NovoNutrients	Sunnyvale, California-based climate biotech converting industrial CO2 emissions into single-cell protein for aquaculture and pet food via bioreactor fermentation of hydrogenotrophic microbes. Partners include Chevron and Woodside. Founded 2018.	Sunnyvale, United States	Private	$23M
114	Modern Fertility	Women's health company that made fertility hormone testing accessible and affordable through at-home testing kits. The flagship product measured up to 10 fertility hormones via a simple finger-prick, providing personalized reports and fertility timelines. Expanded into ovulation tracking kits, pregnancy tests, and prenatal vitamins. Founded by a former 23andMe product lead after a personal health scare revealed the gap in accessible fertility information.	-	Acquired	$22M
115	Rejuvenate Bio	San Diego-based gene therapy company developing longevity and age-related-disease treatments. Initial pipeline in companion animals (dogs) targeting eventual human applications. Three longevity gene targets: FGF21, sTGFβR2, αKlotho. Spinout from George Church's Harvard/Wyss Institute lab. Founded 2018.	San Diego, USA	Private	$16M
116	Kepler Bio	Cambridge-based biotech engineering CAR-T cell therapies for solid tumor indications. Runs three preclinical programs.	Cambridge, United States	Private	$15M
117	Cinder Bio	Boston-based biotech building AI-designed therapeutic antibodies for rare autoimmune indications.	Boston, United States	Private	$15M
118	Larkspur Biotech	Cambridge-based biotech building AI-designed antibody-drug conjugates for solid tumor indications.	Cambridge, United States	Private	$14M
119	StrainX Bioworks	Bhopal-based Indian synthetic biology company using precision fermentation to produce alternative proteins, nutrition ingredients, materials, and consumer health products at scale. 10,000-liter fermentation demonstrated; targeting 100,000-liter commercial operations.	Bhopal, India	Private	$13M
120	Wren Genetics	Seattle-based biotech startup engineering AI-designed guide RNAs for base-editing therapeutics in cardiovascular indications.	Seattle, United States	Private	$13M
121	Sunrise Bio	Cambridge-based biotech engineering AI-designed cell therapies for autoimmune indications.	Cambridge, United States	Private	$13M
122	Perceptic	London-based AI operating system for drug discovery and clinical development covering asset scouting, scientific evaluation, indication selection, and clinical data analysis. Deployed at top-20 pharma including CSL. Founded 2024 by ex-Palantir AIP and Life Sciences leaders.	London, United Kingdom	Private	$12M
123	Veritas Aortic Solutions	Costa Mesa, California-based developer of the Transcatheter Valved Aortic Root Conduit (TVARC), a catheter-based non-surgical alternative for aortic root and ascending aortic disease. Spun out of inQB8 Medical Technologies in 2024.	Costa Mesa, USA	Private	$12M
124	Cascade Genomics	SF-based clinical genomics startup building AI-guided cardiovascular risk prediction from polygenic scores.	San Francisco, United States	Private	$12M
125	Ember Bio	Boston-based biotech engineering AI-designed CAR-T cell therapies for solid tumor pediatric cancers.	Boston, United States	Private	$12M
126	Elm Genomics	Cambridge-based oncology biotech building an AI-guided drug discovery platform for rare pediatric cancers. Runs 3 preclinical programs in solid tumor indications.	Cambridge, United States	Private	$11M
127	Blueprint Genomics	San Francisco-based clinical genomics startup building AI-driven variant interpretation for rare disease pediatric diagnosis.	San Francisco, United States	Private	$11M
128	Fossil Ventures Biotech	San Diego-based biotech startup applying protein language models to rare orphan-disease target discovery for lysosomal storage disorders.	San Diego, United States	Private	$10M
129	Tarragon Ag	Boulder-based agricultural biotech building precision-fermentation crop protection products for row-crop farmers. Trials in Kansas and Nebraska.	Boulder, United States	Private	$9M
130	Meridian Farmed	Chicago-based food-tech building precision-fermentation cocoa alternative for CPG customers.	Chicago, United States	Private	$8M
131	Goldenrod Therapeutics	Houston, Texas-based precision therapeutics company advancing 11h, an orally bioavailable brain-penetrant PDE4 inhibitor. First target: Friedreich's Ataxia. Then broader neurodegenerative and neuroinflammatory indications. Technology in-licensed from University of Nebraska Medical Center. Founded 2023.	Houston, USA	Private	$7M
132	Almond Foods	Los Angeles-based food-tech startup building AI-designed alternative dairy products for retail launch in 2027.	Los Angeles, United States	Private	$7M
133	Aurora Genomics	Cambridge-based synthetic biology startup building an AI-guided cell-free protein synthesis platform for rapid enzyme discovery. Targets industrial enzymes for detergents, food, and biofuels. Founded 2025.	Cambridge, United States	Private	$6M
134	Radiant Foods	Chicago-based food-tech startup building precision-fermentation dairy proteins for QSR and CPG customers. Ships casein and whey isolate to pilot manufacturing partners.	Chicago, United States	Private	$6M
135	Coral Sciences	Sydney-based ocean-tech startup building AI-monitored coral reef restoration for Great Barrier Reef and Indo-Pacific climate resilience.	Sydney, Australia	Private	$6M
136	Fjord Bio	Bergen-based synthetic biology startup engineering marine microbes for salmon-farm alternative protein and health additives. Backed by SalMar and Grieg Seafood.	Bergen, Norway	Private	$6M
137	Coefficient Bio	Stealth biotech AI startup using AI to accelerate drug discovery and biological research. Founded by former Genentech Prescient Design computational biology researchers. Acquired by Anthropic in April 2026 for $400M, barely 8 months after founding. Team of fewer than 10 people integrated into Anthropic's healthcare and life sciences division.	San Francisco, United States	Acquired	$5M
138	Acurion	Precision oncology technology company developing advanced diagnostic and therapeutic tools for cancer treatment. Combines AI-driven analysis with clinical workflows to enable personalized cancer care at scale.	San Diego, United States	Private	$4M
139	Danaher	Global life sciences and diagnostics conglomerate operating three divisions: Biotechnology, Life Sciences, and Diagnostics. Known for the Danaher Business System (DBS), a continuous improvement methodology. Grew through strategic acquisitions including the $5.7 billion purchase of Abcam in 2023.	Washington, US	Private	-
140	Worldwide Clinical Trials	Global clinical research organization (CRO) providing drug development and clinical trial services across multiple therapeutic areas. Backed by Kohlberg & Company since 2023.	Durham, US	Private	-
141	Catalyst Clinical Research	Specialized multi-therapeutic functional service provider (FSP) and niche oncology CRO for biopharmaceutical and biotechnology companies. Known for expertise in early phase oncology trials.	Wilmington, US	Acquired	-

No results found.